The “Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity” is an international agreement which aims at sharing the benefits arising from the utilization of genetic resources in a fair and equitable way. It entered into force on 12 October 2014.

The Nagoya Protocol imposes a complex set of multi-jurisdictional compliance obligations on businesses active in the pharmaceutical, food, cosmetics and other life science sectors. It now has more than 100 contracting parties, including the EU. The key legal source in the EU is Regulation (EU) No. 511/2014 on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union.

The Protocol consists of three pillars. First, countries may require that a company seeking access to any material of plant, animal, microbial or other biological origin (“genetic resources”), receives a government authorization before acquiring it. Second, those countries may also impose conditions for “equitable benefit-sharing.” For example, they may require that a percentage of the profits from resulting products are paid to a public fund in that country (e.g. South Africa). Countries that impose such access and benefit-sharing (“ABS”) conditions are called provider countries. Third, all 100+ parties to the Nagoya Protocol must enforce compliance with the ABS-requirements of the provider countries. These are called “user countries.”

Germany has also signed the Nagoya Protocol and enacted national legislation to implement the obligations under the Nagoya Protocol and under the Regulation (EU) 511/2014. Based on this law, the German Federal Agency for Nature Conservation (Bundesamt für Naturschutz) as the competent authority has recently taken regulatory steps to further implement and enforce the Nagoya Protocol. As such, the competent authority has now started specific outreach to pharmaceutical companies in Germany and requests detailed information about the companies’ measures taken to ensure compliance with the Nagoya Protocol. The German authority, among other things, also asks whether the companies have accessed genetic resources since October 2014 and whether they have developed a product based on the use of genetic resources. Companies are obliged to respond to these requests for information. Violations of the Nagoya Protocol obligations may be subject to regulatory fines.

On 9 May 2018, the German authority has also issued a general decree and requests all recipients of research funding involving the utilization of genetic resources and traditional knowledge associated with genetic resources to declare that they exercise due diligence in accordance with the laws implementing the Nagoya Protocol (diligence declaration).

The Nagoya Protocol is a compliance challenge for many companies. Especially, pharmaceutical and biotech companies can fall under these rules. Therefore, whenever the company’s business requires R&D on material of biological origin, it is worth examining whether there are obligations under the Nagoya Protocol.

In conclusion, pharmaceutical and other life sciences companies as well as companies in the food and cosmetics sector will need to review their R&D activities and consider implementing measures to consider and to comply with the Nagoya Protocol. If a company finds that Nagoya Protocol obligations are triggered, they may need to request public permits and negotiate benefit-sharing as required in the country of origin of the genetic resources. Companies also need to implement internal compliance measures to meet the legal requirements in the EU. The German regulatory agency has started reviewing these measures and it is likely that it will also enforce against any non-compliance.

Covington has a unique practice focusing on compliance with the Nagoya Protocol, embedded within its global life sciences practice. Our experience covers more than 20 countries in four continents, including Germany.

Source:

General Decree of the German Federal Agency for Nature Conservation (Bundesamt für Naturschutz), Federal Gazette of Germany dated 9 May 2018.

Link to Decree:

https://www.bundesanzeiger.de/ebanzwww/wexsservlet?session.sessionid=93250e469fb2b796fd90a075b1dc53bc&page.navid=detailsearchlisttodetailsearchdetail&fts_search_list.selected=6bcfeee881f585c6&fts_search_list.destHistoryId=07617

 

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Dr. Dr. Adem Koyuncu Dr. Dr. Adem Koyuncu

Adem Koyuncu is double qualified as a lawyer and medical doctor and a partner in our Brussels and Frankfurt office. He is a chair of the firm’s “Food, Drug & Device” practice group and also a member of our Compliance practice. Adem is…

Adem Koyuncu is double qualified as a lawyer and medical doctor and a partner in our Brussels and Frankfurt office. He is a chair of the firm’s “Food, Drug & Device” practice group and also a member of our Compliance practice. Adem is recognized as a “leading lawyer for pharma and medical devices law” (JUVE).

Adem is a life sciences industry advisor with more than 25 years of professional experience. He has a broad practice that cuts across regulatory, compliance, IP, privacy and liability matters. Adem also provides strategic advice. He knows the life sciences sector also from his earlier work in the pharmaceutical industry and as a medical doctor. He represents clients before courts and authorities and assists them in contract negotiations, investigations and transactions. For years, Adem is listed in various lawyer rankings.

See some Accolades from Clients and Surveys:

“Adem Koyuncu is one of the most intelligent lawyers I know.” (Legal 500 2023)
“He is one of the most detail-oriented and client-focused partners I have ever encountered.” (Client, Chambers 2021)
“Great professional and human competence, good team player.” (Client/Adverse Party, JUVE 2022)
“I find him to be one of the most pragmatic regulatory lawyers. He was a doctor before a lawyer, has been in-house, worked on lots of stuff that I have to handle in-house, which helps when getting advice. He is really good at saying it’s a complex situation and your best option is to do this.” (Chambers 2022)
“He always comes through with extremely helpful advice. He brings a unique understanding and experience to his practice as both a lawyer and medical doctor.” (Chambers 2021)
“He is an excellent dispute resolution lawyer and advises at the highest level, including, in particular, strategic advice.” (Legal 500 2023)
“He is very sharp and quick, while at the same time having a good sense of humor and nerves of steel. Very pleasant to work with.” (Legal 500 2022)
He is described as “versatile competent, reliable and high quality” (JUVE 2021) and “incredibly fast.” (JUVE 2018)
Provides advice at “an outstanding level.” (Legal 500 2015)
“Very strong negotiation skills.” (JUVE 2011)
Clients appreciate his “very broad knowledge and long-standing expertise” (JUVE 2021/22) and that “he is approachable, knowledgeable and really easy to talk to over the various issues. He is calm and has seen most problems before.” (Chambers 2020)
Peer lawyers described him as “highly competent” and a “very good and pleasant lawyer” (JUVE 2014) and as “the off-label-guru, substantively very good, creative.” (JUVE 2022)

Adem is the author of numerous publications (e.g., in leading books on pharma law, product liability and clinical trials) and frequent speaker at different events. As such, he will soon speak at following events:

Speaker at webinar “Germany Life Sciences Update – Spotlight: Clinical Trials,” (9/12/2025)
“The new EU Product Liability Directive and its implications for pharmaceutical companies and their compliance officers,” 33th AKG Compliance Officer-Meeting (in German), Berlin (11/26/2025)
“The Information Officer – Responsible Person under § 74a AMG,” Seminar, Munich (February 3, 2026)

Photo of Bart Van Vooren Bart Van Vooren

Bart Van Vooren, partner leads a dynamic practice at the intersection of EU regulatory law, global health, and biodiversity law. In these fields, he advises innovative pharmaceutical, food, cosmetic and technology companies on complex EU and global regulatory, compliance and policy assignments.

Bart…

Bart Van Vooren, partner leads a dynamic practice at the intersection of EU regulatory law, global health, and biodiversity law. In these fields, he advises innovative pharmaceutical, food, cosmetic and technology companies on complex EU and global regulatory, compliance and policy assignments.

Bart holds a Ph.D. in EU and International Law and was a professor of EU law until 2013. During that time, he wrote the first-ever handbook with Cambridge University Press on “EU External Relations Law” (2014). He then transitioned to private practice, and frequently acted for the Belgian government before the EU Court of Justice (e.g. C-16/16P Belgium vs Commission). Bart joined Covington in 2016, leading some of our most consequential EU litigation proceedings (e.g. C-311/18 “Schrems II”) over the years.  Having handled nearly 50 cases before the EU Court, he’s uniquely qualified to support our corporate clients in our most high-stakes disputes. Recent examples include T-189/21 Aloe Vera of Europe v Commission (which we won, so the Commission decided to appeal); as well as T-201/21 Covington & Burling and Van Vooren v Commission (which we also won, and hence is also on appeal).

As a pioneer in biodiversity law, over the past 15 years Bart has built a unique, global practice on Access and Benefit-Sharing (ABS) laws under the Convention on Biological Diversity, the Nagoya Protocol, the Plant Treaty, the High Seas Treaty and the WHO Pandemic Agreement. ABS compliance is critical when sourcing biological materials for life sciences R&D and I work with many of the world’s innovative life sciences companies on the whole range of e.g. transactional, contractual, compliance, IP, (EU) regulatory and litigation work relating to ABS. As biodiversity has increasingly become identified as a major commercial and financial risk to companies, so has the practice expanded to e.g. biodiversity credit markets, biodiversity insurance, biodiversity claims and advertising, and so on. Since April 2025, Bart has been appointed as the industry representative to the Steering Committee of the UN Biodiversity Fund that seeks funding from the private sector for biodiversity conservation and restoration.

Bart also pioneered our global health practice. He has advised pharmaceutical clients on seasonal and pandemic influenza since 2016. Since then, this practice area expanded to cover all matters relating to infectious diseases, and as of 2020, emergency preparedness and response (eg. WHO prequalification, International Coordination Group negotiations, Emergency Use Listing, International Health Regulations Rev 2024). He has been the pharmaceutical industry’s lead lawyer advising on the WHO Pandemic Treaty negotiations, adopted on 14 May 2025. Currently, he continues to advise on the work of the Intergovernmental Working Group (“IGWG”) teasing out the technical details of the “Pathogen Access and Benefit-Sharing System” intended to create legally binding obligations on companies to commit vaccines, therapeutics and diagnostics in case of a new global health emergency.

In Chambers rankings, clients have kindly described Bart as “very knowledgeable, action-focused and service-focused lawyer”, adding that he “really tries to find a way of working through challenges”, am “customer-oriented” and provide “sound advice and reasonable options for our business with pros and cons.”

Finally, Bart has an active pro bono practice assisting NGOs defending the human rights of persons with a disability through strategic litigation before the EU Court.